FROM JAMA-ENDORSED MEDICAL HARM REDUCTION TO CHILD SUBSTANCE USE EPIDEMIC
Another Medical Industry Predictable Public Health Threat – Vaped Nicotine Booming Among Youth Linked to Increased Cigarette Use and Diabetes Epidemic
by Clark Miller
Published April 5, 2019
Updated April 7, 2021; October 13, 2021
Below – UPDATE: NEW EVIDENCE OF TROUBLING YOUTH DIABETES TRENDS CONSISTENT WITH PREDICTED EFFECTS OF INCREASING NICOTINE USE WITH VAPING
Accumulating evidence points to runaway rates of “vaping” of nicotine among youth, now characterized as posing unknown risks and as an epidemic warranting investigation by the Food and Drug Administration (FDA) who last year announced plans for promotion of e-cigarettes as harm reduction, a strategy endorsed in the nation’s leading medical journal.
And is increasing rates of youth who will smoke tobacco.
Endorsement of the FDA plan in the Journal of the American Medical Association (JAMA) cited a small downward shift in vaping by youth over just one year- 2016. But as described in new reports in the online news source Vox and increasingly elsewhere, more recent data point to booming use of e-cigarettes among youth, that use increasing likelihood of young people starting to smoke (tobacco) cigarettes.
Additional takeaways from the 2018 report on e-cigarette use by the National Academies of Sciences, Engineering, and Medicine include:
– long term health effects are not known
– the evidence is not clear as to whether use of e-cigarettes reduces tobacco use
Wait . . . what? Findings of the comprehensive review of available research are mixed:
1) reduced risk of illness from use of e-cigarettes versus tobacco cigarettes yet
2) Instead of switching to e-cigarettes as a substitute, use of e-cigarettes does not appear to decrease prevalence of tobacco use among adults – leaving the question of effectiveness and wisdom of the e-cigarette harm reduction strategy unanswered.
Q: How did vaping go from JAMA-endorsed “harm reduction”- to epidemic?
As outlined in a previous post,
the FDA/Medical Industry plan and endorsement for vaping as effective harm reduction relied on an irresponsibly limited data base; was not grounded in a research base adequate to support confidence in vaping behavior as reducing use of tobacco overall or confidence in vaping health effects as significantly benign compared to those for tobacco; and ignored the direct links among nicotine, risk of onset of type 2 diabetes, and increasing rates of diabetes among youth.
Nicotine, an addictive substance, may be delivered in vape devices in concentrations as high or higher than in regular cigarettes. The delivery and behavioral nature of vaping and smoking predict higher potential for conditioned psychological dependence. To a greater degree than other substances, the bioactive delivery of nicotine vaped or smoked, and the comforting behavioral ritual, are repeated many times each day, with each inhalation, up to hundreds of times each day. That is, the cycle of felt need or compulsion to deliver the mood-altering substance, its delivery by inhalation, and the rewarding sensory/mood alteration are repeated many to hundreds of times each day. That’s a lot of positive reinforcement of the behavior.
From research and findings linked to in this follow-up post, accumulating evidence heightens concerns pointing to unknown risks of vaping for adults and especially youth, and known risks in the context of apparent rapidly increasing use of vaping among youth.
For example, teens who start vaping are more likely to continue than to quit, and more likely to start smoking tobacco; vaping may not help cigarette smokers quit; and surveyed, non-randm samples of youth and adults who have started vaping have indicated little motivation to stop.
And congruent with accumulating evidence pointing to a gateway rather than proactive link from vaping to cigarette use and nicotine dependence – illustrated here, new CDC data appear to point to an uptick in teen use of cigarettes this year (from 2017) by 7%, after decades of decline concurrent with the sharp upturn in vaping over past years.
New Canadian public health figures – for e-cigarette and cigarette use among Canadians 15 years of age and older – appear to model those alarming U.S. trends. Prevalence of that population in Canada having ever used e-cigarettes increased by 15% in 2017 compared to 2015. And concurrently with the increased use of vaping, instead of the desired and industry-promoted projection of decreased cigarette use related to vaping, instead cigarette use increased, also by 15%, over the same period. As in the U.S., cigarette use had apparently prior to the upturn been in decline, “In 2017, the overall prevalence of smoking among Canadians aged 15 and up was 15 per cent, representing 4.6 million current smokers, an increase from 2015 when it hit an all-time low of 13 per cent.”
the cycle of felt need or compulsion to deliver the mood-altering substance, its delivery by inhalation, and the rewarding sensory/mood alteration are repeated many to hundreds of times each day. That’s a lot of positive reinforcement
Now it appears that France has joined the U.S. and Canada for the alarming and predictable trend. Vaping there has increased among youth since its introduction and marketing began a decade or so ago.
Noted in this 2017 report, in 2016 more than half (53%) of French 17-year-olds had tried vaping, and 2 percent had become daily users. And their use of tobacco cigarettes increased, for 17-year-olds, “the downward trend in daily smoking observed between 2000 and 2008 reversed, with a slight increase over the 2008 – 2014 period.”
More recently, epidemiological data on vaping among youth and adults at risk of increasing use of tobacco cigarettes and nicotine dependence was released by the American Academy of Pediatricians.
“With our findings, we suggest that smoking uptake and progression is an adverse public health consequence of high rates of e-cigarette use among youth and young adults. The findings also did not reveal strong evidence of transitioning away from combustible cigarette use as a potential public health benefit of e-cigarette use in young people. Together, these findings reveal that adolescent e-cigarette use may result in an overall adverse impact on the public health of youth and young adults.”
Remarkably, the esteemed Academies and Medical Industry reviews and recommendations along with media analyses of results, policy, and implications for public health have not yet addressed the concurrent public health epidemics directly impacted by proposed use of an FDA vaping promotion campaign –childhood and adult diabetes epidemic fueled partly by nicotine use.
The missing, potentially lethal, epidemic links – missing from the scientific reviews, medical industry recommendations, and media accounts- include:
direct effects of nicotine on risk of onset of type 2 diabetes and worsening of diabetes
normalization and worsening (increase) of nicotine use in youth and adults by trends in e-cigarette use, encouraged by harm-reduction strategies,
the diabetes public health epidemic described as posing the greatest risk to public health , looming and fueled by increased latent risk from a childhood obesity epidemic.
“A meta-analysis found that current smokers had a 45% increased risk of developing diabetes compared with nonsmokers.”
“Nicotine, acknowledged as the major pharmacologically active chemical in tobacco, is responsible for the association between cigarette smoking and development of diabetes.”
That’s not good.
UPDATE: NEW EVIDENCE OF TROUBLING YOUTH DIABETES TRENDS CONSISTENT WITH PREDICTED EFFECTS OF INCREASING NICOTINE USE WITH VAPING
Pediatricians are raising alarms about new evidence for increasing prevalence of type 1 and type 2 diabetes over the past two decades, based on a 2021 report in JAMA.
The findings appear more consistent with effects related to the known direct relationships among nicotine and risk of development of diabetes and surging nicotine use in youth tied to the vaping epidemic than to effects of persistent increases in youth obesity alone, another significant risk factor.
From the JAMA report –
For type 1 diabetes, increases appear larger for ages 10 to 19 compared to younger children, the older age range affected differentially by increased nicotine use and not differentially by other identified factors for risk of diabetes.
For type 2 diabetes, increases in prevalence appear greater for ages 15 to 19 compared to 10 to 14 and for that 15 – 19 group greater for the time period 2009 to 2017 that includes years after youth vaping of nicotine surged, compared to 2001 to 2009, prior to significant onset of youth vaping.
Childhood obesity and overweight have been increasing generally for all age groups over past years and decades, so don’t seem able to account for the observed differential pattern in increasing prevalence in diabetes that are associated with time frame and ages most likely to represent effects of increased nicotine use due to vaping. Across youth ages 13 to 18, prevalence of vaping increases significantly and consistently from younger to older, consistent with the apparent differences in increases in diabetes rates.
The findings for youth diabetes trends unfortunately do not include data after 2017, and these findings are open to multiple interpretations. Additional evidence will be required to evaluate population effects on youth diabetes incidence related to known risk related to nicotine use and epidemic increases in youth delivery of nicotine by inhalation
Mounting evidence connects links among accumulating research, findings, risk and harm:
Vaping is booming among young people
Driven by popularity of shrewdly advertised, designed, and marketed devices to deliver nicotine
In concentrations similar to or possibly higher than delivered in cigarettes
As often preferred by users
The retained dependence on nicotine supporting durable use of vape devices
Without consistent or convincing evidence of benefit as cessation aid for use of cigarettes
Instead evidence of “gateway” effect, or prediction of initiation of cigarette use
The presumed net benefit of vaping substituted for cigarette use not established, with long-term population effects of increased prevalence of nicotine dependence unknown
And alarming in the context of known health risks of nicotine regardless of delivery system, including contribution to incidence of type 2 diabetes, increasing in youth
Now, independently in the U.S., Canada, and France – epidemiological data
predicted by those results and links contribute to evidence of failed outcomes, again, for medical industry harm reduction fixes for the non-medical problem of compulsive substance use. As vaping – not long ago endorsed in the nation’s leading medical journal as a form of harm reduction – booms among youth, concurrently historical trends in decreased use of tobacco smoked in cigarettes now appear to be reversing and apparently increasing in those three populations.
The congruence of those trends with the accumulating evidence pointing to a gateway rather than proactive link from vaping to cigarette use and nicotine dependence appears to form another disturbing example of medical/pharmacologic fixes for non-medical problems, predicting harm.
More than four months ago, the predictable, disturbing trend in reversing incidence of youth cigarette smoking – after decades of decline and associated with booming vaping – was reported on and discussed here. It took four months for major media to pick up on the lethal trend, and without examination of the similar trends in Canada and France.
UPDATE: NEW EVIDENCE FROM IRELAND POINTS TO THE SAME VAPING-INDUCED UPTURN IN YOUTH CIGARETTE SMOKING AFTER DECADES OF DECLINE
For the first time in 25 years, rates of smoking among teenage boys in Ireland are increasing, according to a study published in ERJ Open Research.
The study also shows that rates of vaping among teenagers have risen in the last four years and that teenagers who use e-cigarettes are more likely to smoke.
The researchers say their findings indicate that Ireland will not meet its targets to reduce smoking rates and they add to evidence that vaping could be promoting a new generation of young people addicted to nicotine.
Regularly, new evidence mounts confirming that instead of a protective effect, booming vaping among youth acts as a “gateway”, increasing likelihood of initiation of use of tobacco by smoking (cigarettes). Playing a key role in creation of the epidemic, media reporting on vaping and its consequences for public health evidence the same remarkable incompetence, ignorance and craven service to Medical and substance delivery industries as in major media collaboration with Big Medicine, Big Pharma, NEJM, others to message the lethal fabrications enabling the opioid crisis.
A recent egregious and illustrative example, described in this recent post, in which ignorance of and inability to integrate critical thought with understanding of the most basic of concepts of experimental design – the control group in a randomized controlled trial (RCT) – generated unsupportable conclusions about effectiveness of both nicotine replacement therapy (NRT) and vaping for cessation of smoking (of tobacco cigarettes), those constructed, unsupported distortions promoted on major media, then knowingly and enthusiastically endorsed on social media by academics, professionals, popularizing writers, others.
Turns out, based on trends and accumulating evidence, that encouraging adults and kids to believe in the safety of vaping a highly addictive substance directly linked to looming diabetes epidemics and with unknown health risks was a really, really bad idea.
From the start.
As bad an idea as continuing to encourage smokers to believe that nicotine replacement therapy = NRT (like nicotine patches), and prescribed medications to stop smoking are effective, in the face of evidence establishing no or insignificant benefit, and predicted increased risk for relapse – those outcome failures contributing to the opioid crisis through the effects of nicotine and smoking on chronic pain and problem use of alcohol and opioids.
As bad, potentially, as the runaway prescription, against all lines of longstanding available evidence, of highly addictive opioid pain medications for centralized (common) chronic pain, an entirely non-medical, psychogenic problem, with no indicated biomedical treatments instead indicated evidence-based, durable psychotherapy (CBT) interventions.
And generating this.
As bad an idea
as continuing to implement and falsely promote prescription and provision of substitute opioids of abuse without associated evidence-based treatment, as a “fix” and “gold standard” for that generated, iatrogenic opioid crisis. While evidence mounts that the associated national opioid epidemic is worsening, including diversion, abuse, and increasing association of those prescribed opioids in overdose deaths.
That bad an idea.
The more the gold standard medical fix is prescribed for diseased brains, the more deaths.
as continuing to promote a fictional model of “addiction” as a medical condition, “disease of the brain” invalidated by all relevant lines of longstanding evidence, diverting decades and billions of dollars of public healthcare resources away from evidence-based treatments, while national substance use epidemics worsen. Diverted on the false and lethal promises of magic pills just around the corner, for vulnerable Americans trapped in substance use problems.